New Content  edit
Get The App!

Loading the player...
Update on JAK Inhibitor — COMFORT II Trial interview with Claire Harrison, MD, at ASH 2011
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
At the American Society of Hematology (ASH) 2011, Claire Harrison, MD, discusses the updated analysis of the COMFORT II Study, which includes the significance of a 35% reduction in spleen volume in all subgroups. Also discussed are health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy, as well as other pertinent clinical information.

Accompanying this interview are two downloadable slide decks of the abstracts.